BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.140
-0.070 (-5.79%)
At close: May 15, 2026, 4:00 PM EDT
1.220
+0.080 (7.02%)
After-hours: May 15, 2026, 7:16 PM EDT

BioXcel Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
31361988605569
Market Cap Growth
205.59%92.59%-78.99%-85.40%6.29%-49.58%
Enterprise Value
113.9891.6391.27124.11504.71336.97
Last Close Price
1.141.605.9847.20343.68325.28
PE Ratio
--0.28-0.25-0.48-3.63-5.02
PS Ratio
50.9955.658.1963.981612.26-
PB Ratio
--0.37-0.20-1.567.872.57
P/TBV Ratio
-0.18-0.20-0.16-1.527.842.42
P/FCF Ratio
--0.62-0.26-0.57-4.46-6.89
P/OCF Ratio
--0.62-0.26-0.57-4.47-6.92
EV/Sales Ratio
177.54142.7340.2889.941345.89-
EV/EBITDA Ratio
--1.83-1.36-0.72-3.17-3.16
EV/EBIT Ratio
--1.82-1.36-0.72-3.16-3.15
EV/FCF Ratio
--1.59-1.27-0.80-3.73-4.08
Debt / Equity Ratio
-0.74-0.89-1.10-1.791.220.00
Debt / EBITDA Ratio
-1.99-2.18-1.53-0.59-0.59-0.01
Debt / FCF Ratio
-1.75-1.90-1.42-0.65-0.69-0.01
Net Debt / Equity Ratio
-0.79-0.85-0.78-0.63-1.30-1.05
Net Debt / EBITDA Ratio
-1.65-1.61-1.09-0.210.632.17
Net Debt / FCF Ratio
-1.45-1.40-1.01-0.230.742.81
Asset Turnover
-0.020.040.010.000
Inventory Turnover
0.710.231.610.630.02-
Quick Ratio
0.320.541.352.395.9013.98
Current Ratio
0.620.831.682.656.1714.21
Return on Equity (ROE)
74.96%74.14%79.67%-1766.94%-111.08%-49.93%
Return on Assets (ROA)
-128.16%-121.22%-120.04%-122.90%-71.70%-46.56%
Return on Invested Capital (ROIC)
1166.49%624.87%425.59%897.57%1077.12%1492.46%
Return on Capital Employed (ROCE)
337.47%-1422.44%-215.05%-156.60%-80.68%-49.64%
Earnings Yield
-213.52%-358.13%-393.14%-208.33%-27.56%-19.92%
FCF Yield
-176.00%-161.27%-388.29%-175.58%-22.41%-14.52%
Buyback Yield / Dilution
-381.58%-381.58%-39.21%-4.00%-6.23%-21.63%
Total Shareholder Return
-381.58%-381.58%-39.21%-4.00%-6.23%-21.63%
Updated May 15, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q